EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieStudienprotokoll

Results of a Phase II Trial for Intermediate‐Risk Rhabdomyosarcoma Treatment Protocol JRS‐I: A Report From the Japan Rhabdomyosarcoma Study Group

Atsushi Kikuta iD, Hidekazu Masaki, Hiroshi Hojo, Jun-Ichi Hata, Hajime Ohkita, Hajime Hosoi, Atsuko Nakazawa, Shiro Hinotsu, Hitoshi Ikeda, Seiji Kishimoto, Michio Kaneko, Akira Kawai und 7 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31894 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Atsushi Kikuta und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Rhabdomyosarcoma. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Cancer Research by the Ministry of Health, Scientific Research by the Ministry of Health, Research by the Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the safety and efficacy of multimodality treatment with vincristine, actinomycin D, and cyclophosphamide (VAC) therapy, surgery, and radiotherapy according to the US Intergroup Rhabdomyosarcoma Study IV (IRS‐IV), and to establish a central review system and standard treatment for intermediate‐risk pediatric rhabdomyosarcoma in Japan. Patients and methods The Japan Rhabdomyosarcoma Study‐I (JRS‐I) was a single‐arm, phase II trial for intermediate‐risk rhabdomyosarcoma treatment with open enrollment from June 2004 to March 2009. Patients received 12 cycles of VAC every 3 weeks for 42 weeks, with local therapy beginning after Week 12. The endpoints were progression‐free survival (PFS), overall survival (OS), and incidence of hepatic veno‐occlusive disease (VOD).

Results

Thirty‐one eligible patients were enrolled, and at a median follow‐up of 5.2 years, the 3‐year PFS and OS for patients were 74.2% ± 7.9% (95% confidence interval [CI] 55.0%–86.2%) and 90.3% ± 5.3% (95% CI 72.9%–96.8%), respectively. VOD occurred in 3 (8%) of the 40 evaluable patients, but all recovered, and there were no deaths.

Conclusion

The VAC regimen for intermediate‐risk rhabdomyosarcoma with the first central review system in Japan is safe and feasible, and these findings can be positioned as basic data for improving treatment outcomes in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsRhabdomyosarcomaHumansMaleFemaleChild, PreschoolVincristineCyclophosphamideChildInfantDactinomycinSurvival RateAdolescentFollow-Up StudiesJapanCombined Modality TherapyPrognosis

Stichwörter der Autor:innen

outcomes researchpediatric oncologyphase ii clinical trialsrhabdomyosarcomaveno‐occlusive disease

Substanzen

VincristineCyclophosphamideDactinomycin

Autor:innen und Institutionen

  • Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
  • Department of Radiology, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Diagnostic Pathology, Fukushima Medical University, Fukushima, Japan.
  • Central Institute for Experimental Medicine and Life Science, Tokyo, Japan.
  • Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID-Profile: Atsushi Kikuta

Förderung

  • Cancer Research by the Ministry of Health
  • Scientific Research by the Ministry of Health
  • Research by the Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Kikuta, A., Masaki, H., Hojo, H., Hata, J. I., Ohkita, H., Hosoi, H., Nakazawa, A., Hinotsu, S., Ikeda, H., Kishimoto, S., Kaneko, M., Kawai, A., Hara, J., Takimoto, T., Kato, M., Kaneko, T., Kosaka, Y., Morikawa, Y., & Japan Rhabdomyosarcoma Study Group (JRSG) (2025). Results of a Phase II Trial for Intermediate‐Risk Rhabdomyosarcoma Treatment Protocol JRS‐I: A Report From the Japan Rhabdomyosarcoma Study Group. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31894

Vancouver

Kikuta A, Masaki H, Hojo H, Hata JI, Ohkita H, Hosoi H, et al. Results of a Phase II Trial for Intermediate‐Risk Rhabdomyosarcoma Treatment Protocol JRS‐I: A Report From the Japan Rhabdomyosarcoma Study Group. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31894

BibTeX
@article{Kikuta2025,
  author = {Kikuta, Atsushi and Masaki, Hidekazu and Hojo, Hiroshi and Hata, Jun-Ichi and Ohkita, Hajime and Hosoi, Hajime and Nakazawa, Atsuko and Hinotsu, Shiro and Ikeda, Hitoshi and Kishimoto, Seiji and Kaneko, Michio and Kawai, Akira and Hara, Junichi and Takimoto, Tetsuya and Kato, Miho and Kaneko, Takashi and Kosaka, Yoshiyuki and Morikawa, Yasuhide and Japan Rhabdomyosarcoma Study Group (JRSG), Japan Rhabdomyosarcoma Study Group (JRSG)},
  title = {Results of a Phase II Trial for Intermediate‐Risk Rhabdomyosarcoma Treatment Protocol JRS‐I: A Report From the Japan Rhabdomyosarcoma Study Group},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31894}
}
Kostenlos starten →